Verve Therapeutics Inc
NASDAQ:VERV

Watchlist Manager
Verve Therapeutics Inc Logo
Verve Therapeutics Inc
NASDAQ:VERV
Watchlist
Price: 11.13 USD Market Closed
Market Cap: $992.1m

Net Margin

-303.6%
Current
Improving
by 2 209.9%
vs 3-y average of -2 513.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-303.6%
=
Net Income
$-181m
/
Revenue
$59.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-303.6%
=
Net Income
$-181m
/
Revenue
$59.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Verve Therapeutics Inc
NASDAQ:VERV
988.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 15 072 companies
10th percentile
-303.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Verve Therapeutics Inc
Glance View

Market Cap
992.1m USD
Industry
Biotechnology

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. The company is headquartered in Cambridge, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2021-06-17. The firm is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The company is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The firm's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The firm's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

VERV Intrinsic Value
1.06 USD
Overvaluation 90%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-303.6%
=
Net Income
$-181m
/
Revenue
$59.6m
What is Verve Therapeutics Inc's current Net Margin?

The current Net Margin for Verve Therapeutics Inc is -303.6%, which is above its 3-year median of -2 513.6%.

How has Net Margin changed over time?

Over the last 3 years, Verve Therapeutics Inc’s Net Margin has increased from -15 876.3% to -303.6%. During this period, it reached a low of -15 876.3% on Sep 30, 2022 and a high of -303.6% on May 1, 2025.

Back to Top